✨ Free AI Report
Myriad Genetics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Myriad Genetics, Inc.
Company Research

Myriad Genetics, Inc.: Business Overview, Financials & Competitive Analysis

Myriad Genetics is an American molecular diagnostic testing and precision medicine company based in Salt Lake City that offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. The company...

Analyst-debate audio for Myriad Genetics, Inc.

AskCyborg analysts argue the bull and bear cases for Myriad Genetics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Positioned for profitability inflection in 2026 with strong hereditary cancer franchise momentum and upcoming MRD product launch...

Read the full analyst-debate transcript →
Industry Molecular Diagnostic Testing & Precision Medicine
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Myriad Genetics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Myriad Genetics, Inc. Overview

Pro stress-test →

Myriad Genetics is an American molecular diagnostic testing and precision medicine company based in Salt Lake City that offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. The company employs proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and guide development of products assessing disease risk, drug response, and disease progression.

Strategic Profile

Pro stress-test →

Management is focused on the Cancer Care Continuum strategy, aiming to capture more revenue per patient by offering a suite of tests from risk assessment to therapy selection and prognosis, designed to increase test utilization and reduce reliance on any single product. Hereditary cancer testing showed particularly strong momentum with 10% volume growth for full year 2025 and 12% in Q4, while mental health testing volumes grew 6% for the year despite headwinds from payer policy changes.

Competitive Landscape

Pro stress-test →

Myriad maintains a license collaboration with Illumina, Inc. Major competitors in genetic testing include Guardant Health (liquid biopsy), Veracyte (molecular diagnostics), Natera (reproductive and oncology testing), NeoGenomics (cancer diagnostics), and Qiagen (molecular diagnostics). Myriad's competitive advantage derives from its established market position in hereditary cancer testing and expanding Cancer Care Continuum strategy, though it faces pricing pressure from payers and competition from larger diagnostics firms.

Industry Context

Myriad Genetics, Inc. operates in Molecular Diagnostic Testing & Precision Medicine.

Key facts

Founded: 1991 · Headquarters: Salt Lake City, United States · Employees: 2,700 · Revenue: $824.5M · Market cap: $497.8M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Myriad Genetics, Inc..

  • Full year 2025 revenue of $824.5 million with adjusted gross profit of approximately $579 million and adjusted EBITDA of $39 million, maintaining strong liquidity of $225 million
  • Updated MyRisk HCT was launched in Q4 with plans to introduce disease-specific panels in 2026 to broaden addressable market
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Stock trading at $5.01 with recent Q4 2025 earnings beat; analysts project return to profitability in 2026
  • January 2026Sam Raha announced as President and CEO; company provided 2026 financial guidance with strong growth expectations
  • +1 moreTrack every material event for Myriad Genetics, Inc. as it happens. Explore monitoring →
Get alerted when Myriad Genetics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Guardant HealthLiquid biopsy and oncology genomic testing→VeracyteMolecular diagnostics for cancer and thyroid conditions→NateraReproductive and cancer genomic testing→NeoGenomicsCancer diagnostics and companion diagnostics→

Compare Myriad Genetics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Myriad Genetics, Inc. operates in Molecular Diagnostic Testing & Precision Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Molecular Diagnostic Testing & Precision Medicine research →
NEW · MCP server

Ask your AI assistant about Myriad Genetics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Myriad Genetics, Inc. and its top competitor on Cyborg Score”
“What did Myriad Genetics, Inc. do this quarter?”
“Is Myriad Genetics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Myriad Genetics, Inc. do?+
Myriad Genetics is an American molecular diagnostic testing and precision medicine company based in Salt Lake City that offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. The company...
What is Myriad Genetics, Inc.'s Cyborg Score?+
Myriad Genetics, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Myriad Genetics, Inc.'s main competitors?+
Named competitors include Guardant Health, Veracyte, Natera, NeoGenomics. The full competitive landscape is in the AskCyborg report.
How can I get the full Myriad Genetics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Myriad Genetics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Myriad Genetics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Molecular Diagnostic Testing & Precision Medicine research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Myriad Genetics, Inc.8Veracyte, Inc.8Natera, Inc.5NeoGenomics, Inc.